News & Media

Press Releases

Amolyt Pharma Strengthens Leadership Team with Appointment of Mark Sumeray, M.D., as Chief Medical Officer

Download a PDF copy of this press release: EN FR Industry veteran brings over two decades of global experience in pharmaceutical, medical devices and biotech …

Download a PDF: EN or FR

Amolyt Pharma Announces Positive Results from First Patient Cohort of Phase 2a Trial of AZP-3601 for the Treatment of Hypoparathyroidism

Download a PDF copy of this press release: EN FR Four abstracts accepted as poster presentations for the Endocrine Society’s Annual Meeting LYON, France, and …

Download a PDF: EN or FR

Amolyt Pharma Announces Abstracts Accepted for Presentation at ECE and ENDO

Download a PDF copy of this press release: EN FR LYON, France, and Cambridge, MA, May 16, 2022 — Amolyt Pharma, a global company specialized …

Download a PDF: EN or FR

Presentations

  • All PRESENTATIONS
  • AZP-3813
  • AZP-3601
All PRESENTATIONS
  • All PRESENTATIONS
  • AZP-3813
  • AZP-3601
AZP-3601

Living With an “Invisible Disease”: A Qualitative Study With Patients With Hypoparathyroidism

AZP-3813

Sustained Suppression of IGF1 with AZP-3813, a Bicyclic 16-Amino Acid Peptide Antagonist of the Human Growth Hormone Receptor and a Potential New Treatment for Acromegaly. ENDO 2022 Presentation.

AZP-3813

Sustained Suppression of IGF1 with AZP-3813, a Bicyclic 16-Amino Acid Peptide Antagonist of the Human Growth Hormone Receptor and a Potential New Treatment for Acromegaly. ENDO 2022 Poster.

AZP-3813

AZP-3813, a Bicyclic 16-Amino Acid Peptide Antagonist of the Human Growth Hormone Receptor as a Potential New Treatment for Acromegaly

AZP-3601

Healthcare Resource Utilization Burden of Patients with Hypoparathyroidism in the United States

AZP-3601

KOL Webinar on AZP-3601 Featuring John P. Bilezikian, M.D., Ph.D.

AZP-3601

Clinical Burden of Patients with Hypoparathyroidism in the United States: A Claims Data Analysis. ASMBR 2021.

AZP-3601

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics following Single and Multiple Administration of AZP-3601, a Novel Long-Acting PTH Analog, to Healthy Adults. ASMBR 2021.

AZP-3601

Safety, Tolerability and Pharmacodynamics of AZP-3601, a Novel Long-Acting PTH Analog, in Healthy Adults: Data From a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. e-ECE 2021.

AZP-3601

cHP Natural History Study: ISPOR Poster

AZP-3601

A Single Administration of AZP-3601, a Novel, Long-Acting PTH Analog, Induces a Significant and Sustained Calcemic Response: Preliminary Data From a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. ENDO 2021.

AZP-3601

Clinical Burden and Practice Patterns in Patients With Chronic Hypoparathyroidism in the United States (US): A Claims Data Analysis Using Diagnosis Based Criteria. ENDO 2021.

AZP-3601

Clinical Burden and Practice Patterns in Patients With Chronic Hypoparathyroidism in the United States (US): A Claims Data Analysis Using Surgery Based Criteria. ENDO 2021.

Upcoming events

Date: June 1, 2022

Date: June 10 – June 14, 2022 (Atlanta, Georgia)

Date: September 9 - 12, 2022 (Austin, TX)

Social Updates

TWITTER

Scroll to Top